2026 in Review: Medical Cannabis Regulation Across Europe and Latin America

Themes that shaped the year for regulated supply chains, and what to watch heading into 2027.

Context and Why It Matters

Across Europe and Latin America, 2026 continued the gradual shift from pilot programmes and exceptions toward more structured medical cannabis frameworks.

Recurring Themes

Quality expectations converged around GACP at cultivation and GMP at finished product, importers raised their documentation requirements, and traceability became a baseline expectation.

Looking Ahead to 2027

Expect continued attention to pharmacovigilance, stability data, and supply reliability. Specific national changes should always be confirmed with the relevant authority.

Bottom Line

Regulatory maturity rewards suppliers who invest in quality systems before they are required. That remains Hybrida Farms' approach.